Advertisements

Lacks near-term catalysts

■ DBB sees good CHC demand persisting; minimal SCV earnings contribution.
■ No plans to significantly ramp up vaccine manufacturing capacity for now.
■ Downgrade to Hold with lower TP of RM1.60 (18x FY23F P/E).

Advertisements